FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

FDA D.I.S.C.O.: A supplemental drug approval for the adjuvant treatment of high risk advanced renal cell cancer - Transcript

Listen Later
FDA medical oncologists discuss the November 2017 approval of sunitinib for the adjuvant treatment of patients with renal cell carcinoma who are at high risk of recurrence following a nephrectomy.
...more
View all episodesView all episodes
Download on the App Store
FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)By U.S. Food and Drug Administration, Center for Drug Evaluation and Research
  • 4.4
  • 4.4
  • 4.4
  • 4.4
  • 4.4

4.4

14 ratings